Contact

Should Medicine and Public Health Abandon the Opioid Industry’s Terminology Surrounding Pain? An Argument for Conceptual Reclamation and Against Guilt-By-Provenance

Eisenkraft Klein D - Journal of Law, Medicine, & Ethics

  • Commentary & Opinion
| October 2026
  • Regulation and Clinical Evidence

Summary:

VIEW SOURCE
Talk bubble graphics representing commentary and opinion.

LEARN MORE

BROWSE COMMENTARY & OPINION

Recent Work from PORTAL

Talk bubble graphics representing commentary and opinion.

How Congress Can Fix Expert Advisory Committees

Daval CJR, Kesselheim AS - STAT

  • Commentary & Opinion
| October 2026
  • Regulation and Clinical Evidence
View Source
Simple graphic of magnifying glass examining papers to signify reviewing research publications.

International Regulatory Status and Reimbursement Recommendations of Haematological Malignancy Drugs Withdrawn from the FDA Accelerated Approval Pathway

Mulsant SS, Kesselheim AS, Naci H - Journal of Cancer Policy

  • Research Publications
| October 2026
  • Price, Value, and Access
  • Regulation and Clinical Evidence
View Source
An icon of a bill representing government policy.

Comments on FDA Discussion Paper, “Considerations for the Regulation of Generative AI-Enabled Medical Devices”

Jaiswal N, Gorijavolu R, Thomas S, Hwang TJ, Celi LA, Kesselheim AS - Food and Drug Administration (FDA)

  • Policy Interactions
| October 2026
  • Regulation and Clinical Evidence
View Source
VIEW MORE

Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115

©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.